{"filing":{"accession_number":"0001628280-26-052527","cik":"0001396814","ticker":"PCRX","company_name":"Pacira BioSciences, Inc.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"pcrx-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026052527/pcrx-20260804.htm"},"events":[{"id":24033,"run_id":21739,"accession_number":"0001628280-26-052527","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Pacira BioSciences issued a press release on August 4, 2026, announcing its second quarter 2026 financial results, including total revenue of $192.4 million (6% YoY growth), GAAP net income of $4.7 million, and non-GAAP net income of $29.5 million. The disclosure includes detailed financial highlights, segment performance, and updated full-year 2026 guidance. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, which is material to investors assessing the company's financial performance and outlook.","company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24424,"accession_number":"0001628280-26-052527","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Pacira BioSciences issued a press release on August 4, 2026, announcing its second quarter 2026 financial results, including total revenue of $192.4 million (6% YoY growth), GAAP net income of $4.7 million, and non-GAAP net income of $29.5 million. The disclosure includes detailed financial highlights, segment performance, and updated full-year 2026 guidance. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, which is material to investors assessing the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:40:29.562300+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24424,"accession_number":"0001628280-26-052527","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Pacira BioSciences issued a press release on August 4, 2026, announcing its second quarter 2026 financial results, including total revenue of $192.4 million (6% YoY growth), GAAP net income of $4.7 million, and non-GAAP net income of $29.5 million. The disclosure includes detailed financial highlights, segment performance, and updated full-year 2026 guidance. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, which is material to investors assessing the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:40:29.562300+00:00","company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","filing_date":"2026-08-04"}]}